hotspot -WSS

hotspot

author：comprehensive 2025-09-14 21:44:30 - browse：9973

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Long Covid research funding gets a major boost from NIH

WSS

Readout Newsletter: Amgen, Regeneron, BGI Group and more

340B reform proposal comes out of Senate working group

What’s missing from the debate over nursing home staff minimums

Resistance to opioid

Abbott's new heart device gets FDA advisory panel nod

AI gets buy

leisure time

hotspot

entertainment

Walensky prepares to leave CDC — and Congress — behind

Congress considering partial increase for doctor pay in Medicare

Bright Health sells Medicare Advantage business to Molina

Long Covid research funding gets a major boost from NIH

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout LOUD: Venture capital, Gilead, and more M&A

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Amylyx, Aurinia, and IQVIA

As demand for Covid shots wanes, Moderna seeks its next success

Abbott's new heart device gets FDA advisory panel nod

entertainment

Tome Biosciences co

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Report cites 'urgent' need to recruit more diverse clinical trial participants

Websites selling Wegovy, Zepbound ingredients targeted by FDA

AstraZeneca stays mum on Medicare drug pricing negotiations

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

hotspot

focus

focus